close
Fox News Flash top headlines are here. Check out what’s clicking on Foxnews.com.
The European Commission has authorized GSK’s HIV-focused unit ViiV Healthcare’s cabotegravir long-acting injectable and tablets, the British drugmaker said on Tuesday.
EUROPEAN COMMISSION CHIEF URSULA VON DER LEYEN ASSURES AID TO FLOOD-STRICKEN SLOVENIA DURING VISIT
Cabotegravir is recommended in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually-acquired HIV-1 infection in high-risk adults and adolescents weighing at least 77.16 pounds, according to the company.
The GlaxoSmithKline logo is seen in this illustration, Aug. 10, 2022. (REUTERS/Dado Ruvic/Illustration/File Photo)
Sold under brand name Apretude, it is currently approved for use in the United States, Australia, Zimbabwe, South Africa, Malawi, Botswana and Brazil.
CLICK HERE TO GET THE FOX NEWS APP
Things like your name, home address, date of birth and even your Social Security number…
Most people never think about Android security updates until a headline like this appears. Suddenly,…
The next time you pull up to the drive-thru at Burger King, you may notice…
You may think you can spot a crypto scam from a mile away. But what…
The first Tesla Cybercab has officially rolled off the floor at Tesla Gigafactory Texas. And…
Smart glasses promise a future where technology blends into everyday life. You can ask a…